Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Diseases and Illnesses
  5. Covid 19

Covid-19

Thumbnail
August 11, 2022

Valneva throws in the Covid towel

Thumbnail
July 15, 2022

No end to the Novavax deflation

Thumbnail
August 11, 2022

Valneva throws in the Covid towel

Thumbnail
July 15, 2022

No end to the Novavax deflation

Article image
Vantage logo
July 13, 2022

Few biopharma risers stand out at the half year

A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.

Article image
Vantage logo
July 13, 2022

Humanigen is left nursing Covid losses

Article image
Vantage logo
July 04, 2022

US FDA approval tracker: June 2022

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

Article image
Vantage logo
June 16, 2022

Testing times for Roche despite new Covid assay

Article image
Vantage logo
June 09, 2022

Novavax and Moderna continue the fight for Covid relevance

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May 2022

Article image
Vantage logo
May 31, 2022

Go or no go? The FDA’s Amylyx dilemma

June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.

Article image
Vantage logo
May 30, 2022

Move over Humira, it's the cancer antibodies' turn at the top

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Article image
Vantage logo
July 13, 2022

Few biopharma risers stand out at the half year

A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.

Article image
Vantage logo
July 13, 2022

Humanigen is left nursing Covid losses

Article image
Vantage logo
July 04, 2022

US FDA approval tracker: June 2022

Article image
Vantage logo
June 27, 2022

Covid vaccine development could go Omicron-and-on

Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?

Article image
Vantage logo
June 16, 2022

Testing times for Roche despite new Covid assay

Article image
Vantage logo
June 09, 2022

Novavax and Moderna continue the fight for Covid relevance

Article image
Vantage logo
June 01, 2022

US FDA approval tracker: May 2022

Article image
Vantage logo
May 31, 2022

Go or no go? The FDA’s Amylyx dilemma

June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.

Article image
Vantage logo
May 30, 2022

Move over Humira, it's the cancer antibodies' turn at the top

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 10, 2022

Q2 Roundup eBook

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.